These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

891 related articles for article (PubMed ID: 16919870)

  • 21. Clinical practice decisions in endocrine therapy.
    Untch M; Thomssen C
    Cancer Invest; 2010; 28 Suppl 1():4-13. PubMed ID: 20653403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of aromatase inhibitors in adjuvant therapy for early breast cancer.
    Jonat W; Hilpert F; Maass N
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():32-8. PubMed ID: 16273366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
    Hilsenbeck SG; Osborne CK
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
    Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
    Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
    Bauerschlag D; Schem C; Maass N; Jonat W
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant endocrine therapy for early breast cancer.
    Andreetta C; Smith I
    Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended adjuvant endocrine therapy of early breast cancer.
    Chowdhury S; Ellis P
    Curr Med Res Opin; 2005 Dec; 21(12):1985-95. PubMed ID: 16368050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal treatment strategies in hormone-responsive early breast cancer: the role of aromatase inhibitors.
    Untch M; Jackisch C
    Onkologie; 2007 Feb; 30(1-2):55-64. PubMed ID: 17264527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
    Smith IE
    Breast; 2004 Dec; 13 Suppl 1():S3-9. PubMed ID: 15585377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Koeberle D; Thuerlimann B
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):5-10. PubMed ID: 16375638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
    Dixon JM
    Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The evolving role of endocrine therapy for breast cancer].
    Jinno H; Ikeda T; Takayama S; Kitajima M
    Nihon Rinsho; 2006 Mar; 64(3):547-54. PubMed ID: 16529048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant endocrine therapy in breast cancer.
    Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
    Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.